Insider Selling: LeMaitre Vascular, Inc. (NASDAQ:LMAT) Insider Sells $164,979.08 in Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) insider Trent G. Kamke sold 2,009 shares of the business’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the sale, the insider now directly owns 5,564 shares of the company’s stock, valued at approximately $456,915.68. The trade was a 26.53 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

LeMaitre Vascular Trading Up 3.9 %

Shares of LMAT opened at $81.91 on Monday. LeMaitre Vascular, Inc. has a 12-month low of $62.39 and a 12-month high of $109.58. The firm has a 50-day moving average price of $95.21 and a 200 day moving average price of $94.67. The firm has a market capitalization of $1.85 billion, a P/E ratio of 44.76, a P/E/G ratio of 2.22 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.49. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm had revenue of $55.81 million during the quarter, compared to analyst estimates of $55.99 million. Equities research analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 27th. Investors of record on Thursday, March 13th will be issued a $0.20 dividend. The ex-dividend date is Thursday, March 13th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.98%. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.16. LeMaitre Vascular’s dividend payout ratio is currently 41.24%.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. New York State Teachers Retirement System lifted its position in LeMaitre Vascular by 1.2% in the fourth quarter. New York State Teachers Retirement System now owns 8,189 shares of the medical instruments supplier’s stock valued at $755,000 after buying an additional 100 shares during the last quarter. Flputnam Investment Management Co. lifted its position in LeMaitre Vascular by 3.6% in the fourth quarter. Flputnam Investment Management Co. now owns 2,923 shares of the medical instruments supplier’s stock valued at $269,000 after buying an additional 102 shares during the last quarter. Norden Group LLC lifted its position in LeMaitre Vascular by 4.5% in the fourth quarter. Norden Group LLC now owns 2,371 shares of the medical instruments supplier’s stock valued at $218,000 after buying an additional 103 shares during the last quarter. Blue Barn Wealth LLC lifted its position in LeMaitre Vascular by 4.4% in the fourth quarter. Blue Barn Wealth LLC now owns 2,485 shares of the medical instruments supplier’s stock valued at $229,000 after buying an additional 104 shares during the last quarter. Finally, Shaker Investments LLC OH lifted its position in LeMaitre Vascular by 0.8% in the fourth quarter. Shaker Investments LLC OH now owns 13,948 shares of the medical instruments supplier’s stock valued at $1,285,000 after buying an additional 112 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Oppenheimer lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Barrington Research lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Lake Street Capital upped their target price on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Finally, Wells Fargo & Company began coverage on shares of LeMaitre Vascular in a report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 target price for the company. Five investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $95.25.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.